Skip to main content
. 2016 Dec 4;8(10):17347–17359. doi: 10.18632/oncotarget.14468

Figure 5.

Figure 5

Comparisons of VEGF expressions in each group by IHC (× 400) (A, VEGF expressions in the Vector group; B, VEGF expressions in the pcDNA-ANRIL group; C, VEGF expressions in the shANRIL group; D, VEGF expressions in the PDTC group; E, VEGF expressions in the pcDNA-ANRIL + PDTC group. Compared with the Vector group, expression of VEGF was increased in the pcDNA-ANRIL group, while expression of VEGF was decreased in the shANRIL group and the PDTC group. Compared with the pcDNA-ANRIL group, expression of VEGF was evaluated in the pcDNA-ANRIL + PDTC group). Notes: IHC, immunochemistry; PDTC, pyrrolidinedithiocarbamic acid; VEGF, vascular endothelial growth factor; ANRIL, antisense non-coding RNA in the INK4 locus; The Vector group, injected with 800 ng/kg empty plasmid; The shANRIL group, injected with 800 ng/kg lncRNA ANRIL knockout plasmid; The PDTC group, injected with 800 ng/kg NF-κB inhibitor pyrrolidine dithiocarbamate (PDTC); The pcDNA-ANRIL + PDTC group, injected with PDTC after lncRNA ANRIL overexpression; DM, diabetes mellitus; CI, cerebral infarction.